Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Immatics N.V.NASDAQ: IMTX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of €59.19M rose 41.2% year over year, ahead of the +27.4% change in trailing-twelve-month research & development. Sequentially, it rose 19.2% from the prior quarter. Over 3 fiscal years it compounded at +19.9% a year.

Context

  • Research & development amounted to 380.9% of revenue in FY2025, up 285.8 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +41.2% holds above the trailing-twelve-month pace of +27.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€59.19M+19.2% QoQ
Last fiscal yearDec 2025
€183.83M+24.1% YoY
LTMMar 2026
€201.11M+27.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.2%——
1 year+24.1%——
3-year CAGR+19.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

EUR · from the income statement

Latest · FY2025
183.83M EUR
Year-over-year change
+24.1%
4-year CAGR
+20.4%

Research & Development vs competitors

How IMTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +27.4% is the 2nd highest of 11, against a peer median of -7.4%.
  • Research & development amounts to 539.2% of revenue for IMTX, versus a peer median of 118.4%.
IMTX Competitors
Research & Development for IMTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€2.18B EUR-0.6%+9.6%82.6%
LEGNLegend Biotech CorporationLTM Sep 2026$378.58M USD-9.4%+7.3%27.9%
IMCRImmunocore Holdings plcLTM Mar 2026$259.11M USD+17.2%+34.4%67.2%
IMTXImmatics N.V.LTM Mar 2026€201.11M EUR+27.4%+19.9%539.2%
LYELLyell Immunopharma, Inc.LTM Mar 2026$151.83M USD-11.7%-0.1%489780.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$129.09M USD-32.1%-16.3%—
JANXJanux Therapeutics, Inc.LTM Mar 2026$127.65M USD+60.8%+33.1%590.6%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$106.27M USD-5.4%+24.0%1163.2%
CLLSCellectis S.A.LTM Mar 2026$94.68M USD+5.0%-1.4%139.0%
DTILPrecision BioSciences, Inc.LTM Mar 2026$53.36M USD-10.8%+5.5%118.4%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$10.18M USD-92.4%-48.4%44.0%
Peer median (excluding IMTX) —-7.4%+6.4%118.4%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.76M172.83M54M155.84M48.27M
Cost of Revenue87.57M106.78M118.66M00
Gross Profit(52.81M)66.05M(64.67M)155.84M48.27M
Gross Margin-151.9%38.2%-119.8%100.0%100.0%
Research & Development87.57M106.78M118.66M148.08M183.83M
Selling, General & Admin33.81M36.12M38.2M46.45M51.18M
Operating Expenses121.05M142.88M155.72M194.45M230.28M
Depreciation & Amortization5.47M6.84M7.23M12.23M12.4M
EBITDA(87.3M)50.04M(88.93M)34.46M(185.09M)
EBITDA Margin-251.1%29.0%-164.7%22.1%-383.5%
Operating Income(86.29M)29.95M(101.73M)(38.62M)(182.02M)
Operating Margin-248.2%17.3%-188.4%-24.8%-377.1%
Interest Income133K2.48M13.85M25M17.18M
Interest Expense566K1.04M831K886K946K
Other Income / Expenses(7.04M)12.08M4.73M59.96M(16.42M)
Income Before Tax(93.34M)42.04M(96.99M)21.35M(198.44M)
Pre-Tax Margin-268.5%24.3%-179.6%13.7%-411.1%
Income Tax Expense04.55M06.13M(1.99M)
Net Income(95.06M)37.51M(96.99M)15.22M(196.45M)
Net Margin-273.5%21.7%-179.6%9.8%-407.0%
EPS (Basic)(1.51)0.55(1.20)0.14(1.54)
EPS (Diluted)(1.51)0.54(1.20)0.14(1.54)
Weighted Avg Shares62.91M67.22M80.55M108.7M122.35M
Weighted Avg Shares (Diluted)62.91M68.82M80.55M106.8M122.35M

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.